Background and Purpose-The present study investigated the influence of the antiplatelet agent acetylsalicylic acid (ASA) on cerebral microembolism as detected by transcranial Doppler sonography (TCD). Methods-Nine patients with recent transient ischemic attack or minor stroke of arterial origin were investigated. Eight had not received an antiplatelet or anticoagulant medication before TCD, and in 1 patient a preexisting ASA medication (100 mg/d) had not been changed since the onset of stroke symptoms. An initial 1-hour TCD monitoring was extended for an additional 2.5 hours after an intravenous bolus injection of 500 mg ASA and was repeated for 1 hour on the following day. 
L
aboratory and animal models suggest that microembolic signals (MES) detected by transcranial Doppler sonography (TCD) correspond to microbubbles or formed element particles composed of thrombotic or atheromatous material, platelet-rich aggregates, or fat. 1, 2 In patients with symptomatic carotid artery stenosis, MES may correspond to platelet and fibrin particles originating at the stenotic lesion. 3, 4 In these patients, prolonged antiplatelet medication with acetylsalicylic acid (ASA), alone or combined with carotid surgery, is considered the therapy of choice to prevent recurrent stroke. 5, 6 Reduction of cerebral embolism due to cyclooxygenase pathway-related platelet inhibition is the presumed mechanism of ASA action. If MES in patients with symptomatic arteriosclerotic large-vessel disease correspond to arterioarterial emboli, their frequency might be expected to decline after the application of ASA. Until now, however, a decrease of MES due to therapeutic interventions has only been shown for endarterectomy of carotid artery stenosis. 4, 7, 8 We investigated the early effect of ASA on the frequency and time course of MES in patients with transient ischemic attacks or minor strokes of presumably large-arterial-vessel origin.
Subjects and Methods
We present 9 patients (7 men and 2 women; mean age, 56Ϯ12.2 years) referred to the Department of Neurology with transient ischemic attacks (3 patients) or minor strokes attributable to the territory of the middle cerebral artery (MCA). Patients were selected from consecutively referred inpatients and outpatients if they had a recent nondisabling cerebral ischemia of probable arterioembolic origin, had not been started on antiplatelet or anticoagulant medication since the onset of symptoms, exhibited temporal bone windows enabling bilateral TCD insonation, and had given informed consent for the investigations. Symptoms or last symptoms (in case of recurrent events) had occurred 0 to 12 days (median, 6) before MES monitoring. Assessment of extracranial and intracranial brain-supplying arteries by Doppler/duplex sonography and additional digital subtraction angiography (2 siphon stenoses) revealed medium (50% to 69%) or high-grade (Ն70%) stenosis of the carotid artery or MCA of the symptomatic hemisphere in each patient. 9, 10 Transesophageal echocardiography, ECG, Holter monitoring, Doppler CO 2 test, blood samples including vasculitis and coagulation parameters, and CT/MRI scans were normal or revealed findings in accordance with recent atherothrombotic brain ischemia.
Patients underwent bilateral simultaneous MCA monitoring with 2-MHz pulsed wave probes fixed by a metal frame (Multi-Dop X, DWL). For MES detection, we used 64-point fast Fourier transform analysis, 5-mm pulsed wave sample volumes, low gain for Doppler spectra display, and low acoustic intensity (33 mW/cm 2 ). The insonation depth of the (deeper) sample volume ranged from 47 to 59 mm according to the length and depth of the MCA main stem and its bifurcation/trifurcation as evaluated by transcranial color-coded duplex sonography. In case of MCA stenosis, both sample volumes were placed distally. Settings were not changed during an examination and were maintained in follow-up recordings. Continuous MES monitoring was performed for 3.5 hours. After the initial 1 hour, a bolus of 500 mg ASA (Aspisol, Bayer AG) was injected into an antecubital vein. Intravenous application was chosen to exclude any interpatient variability of the rate and extent of absorption, especially with respect to potential ASA effects as early as 30 to 60 minutes after drug administration. 11, 12 Oral ASA administration (300 mg/d) was started the day after the bolus injection, and MES recording (1 hour) was repeated within 2 days (median, 1 day). Recordings were well tolerated by all patients.
With the dual-gated TCD device that was used, MES are identified by their increase of acoustic intensity compared with the background noise (in our setting: whole screen, including Doppler spectrum and spectrumfree areas) and are differentiated from artifacts by the time lag of their appearance in each sample volume. The detection threshold of the relative intensity increase for MES was set to Ն12 dB. In 7 control subjects without history of cerebrovascular disease and with normal extracranial/intracranial sonographic findings, 15-minute bilateral TCD monitoring had revealed a total of 1069 spontaneous spotlike intensity fluctuations within the normal Doppler spectrum in artifact-free periods, reaching a relative intensity increase of 12 dB in only 1 event ( Figure 1 , top panel). The evaluation of the time lag threshold between MES and artifacts was made on the basis of 282 artifacts Ն12 dB that had been produced in control subjects by coughing, clearing their throats, speaking, snoring, swallowing, jaw movements, and tapping against the probe. With the equipment we used, this differentiation is done on the basis of (calculated) distances rather than time measurements, the former calculated as the product of measured time delay and Dopplerderived embolic velocity. 13, 14 As shown in Figure 1 , bottom panel, the calculated propagation distances of artificial events were scattered around 0 mm, not exceeding 0.4 mm in 89.4%. Off-line review of the remaining 30 artifacts with a calculated propagation distance Ն0.5 mm revealed bidirectional high-intensity signals within the lower frequency of the spectrum in 26 cases, which has been described as typical for artifacts. 15 Therefore, periods of interest for MES (relative intensity increase, Ն12 dB; calculated propagation distance, 0.5 to 10 mm) were automatically assessed and registered on-line by the software and reviewed off-line by 2 independent observers, blinded for patients' and monitoring data, with the inclusion of only unidirectional signals within the Doppler velocity spectrum. The 521 events rated by these criteria as MES by both observers (interobserver agreement Ͼ99%; estimated sensitivity for artifact identification Ͼ98%) are characterized in Figure  1 .
In 3 of the 9 patients, venous blood could be collected directly before the administration of ASA (end of initial 1-hour recording) and again 30 minutes after ASA injection. Platelet-rich and platelet-poor plasma were obtained from blood samples (9 mL, anticoagulated with 1 mL trisodium citrate solution, 0.105 mmol/L) by differential centrifugation. Platelet concentration in platelet-rich plasma was adjusted with platelet-poor plasma to 3ϫ10 11 /L. Aggregation in stirred platelet-rich plasma was induced by bovine collagen (Impfstoffwerke Dessau), and the response, measured optically by increasing light transmission, was recorded for 7 minutes (PAP-4C aggregometer, Bio Data Corp, Wellcome Laboratories). Maximal intensity and maximal slope of the aggregation were assessed and compared with corresponding laboratory references from control subjects (lower limit of intensity, 75%; lower limit of slope, 33).
Statistical analysis was performed with the use of SPSS software, version 6.1.3. For each patient, polynomial curves were fit to the scatterplots of (cumulative) MES counts and the time of events to evaluate the best regression model. Curves were fit separately for the preinjection and postinjection periods. For group analysis, the continuous 3.5-hour monitoring was divided into three 1-hour periods (Ϫ60 to 0, 30 to 90, 90 to 150 minutes; time was measured relative to ASA injection at 0 minutes). Frequency of MES in these periods and in the additional 1-hour recording 1 to 2 days after the bolus injection were compared by nonparametric tests for related samples (Friedman 2-way ANOVA, Wilcoxon matched-pair signed rank test). The relative decrease of MES after ASA compared with the corresponding baseline measurement was analyzed by t tests for paired samples. A P value of Ͻ0.05 was considered significant.
Results
During a cumulative monitoring time of 40.5 hours, a total of 521 MES ipsilateral to the symptomatic stenoses were detected. No signals were observed in contralateral MCAs. For the 1-hour preinjection periods, scatterplots of the cumulative MES count and the time of MES appearance were best fit by linear regression models, indicating a constant incidence of MES over time (Figure 2 ). In 7 patients, the frequency of MES decreased after the application of ASA (patients 1 to 7) (Table) . Two of them, who had presented 6 and 18 MES/h before medication, showed no additional signal during continuous 2.5-hour postinjection monitoring. In 5 patients (initial MES rates 13 to 66/h), the incidence started to decrease Ϸ30 minutes after intravenous ASA, indicated by a declining slope of the regression curve ( Figure 2, patient 2) . In 1 patient, MES frequency did not respond to ASA (Table and Figure 2 , patient 8). In the 1 patient who at stroke onset received a preexisting ASA medication of 100 mg/d since former cardiac bypass surgery, only a minor and transient effect could be demonstrated (Table and Figure 2 , patient 9). MES frequencies for each of the 9 patients, as well as mean values of those who showed a decrease after ASA, are presented in the Table . In patients who responded to ASA (patients 1 to 7), the mean MES rate continuously decreased after ASA and was significantly lower than before the 500-mg bolus injection; this was already observed in the 1-hour monitoring period starting 30 minutes after ASA. In 3 of the 7 patients with decreasing MES frequency after ASA, blood samples were drawn for platelet aggregation tests immediately before and 30 minutes after ASA injection. Samples of these patients exhibited normal collagen-induced platelet aggregation before and inhibited aggregability after ASA application (intensity and slope below the lower limit of normal range).
Discussion
There is strong evidence that MES detected in our patients correspond to cerebral microemboli of arterial origin. Embolic signals were only observed in the territory of the symptomatic arterial stenosis, which itself was the only pathological finding detected as a potential source of cerebral microemboli during clinical workup. Criteria for identification of MES and differentiation from artifacts were recently summarized in a consensus statement on cerebral microembolism. 16 Of particular concern was the evaluation of a threshold value between MES and artifacts for the dual-gated time lag of signal appearance, since axial gate distances of Ͻ10 mm and insonation angels of Ն20 degrees (due to the individual course of the MCA and distal placement of sample volumes in case of MCA stenosis) were necessary in a substantial number of our patients. 13, 17 The homogeneous, rapid decline of MES in 7 of our patients may be considered exclusively induced by ASA independently of other potential causes. Clinical setting and technical parameters remained constant during the examinations, which in the 3.5-hour monitoring periods, after the 500-mg bolus injection of ASA, revealed a decline of the mean MES rate in these patients to 12.9% of the preinjection count. A causative relation is also suggested by the strong temporal correspondence between initiation of MES decrease and inhibited platelet aggregation as early as 30 minutes after ASA injection. Because they are undetermined and of minor extent, spontaneous temporal variations of MES frequency in prolonged 18 or recurrent 19 monitoring periods may be considered irrelevant.
With respect to the known rapid effect of ASA on platelet inhibition and the rapid decline of MES observed in 7 patients after ASA, one might assume that MES in these cases mainly corresponded to platelet-rich emboli. However, until now the discrimination of particulate embolic material on the basis of a given Doppler signal has not been possible. 2 Therefore, the lack of effect or only minor effect of ASA on MES frequency in 2 other patients has not necessarily been caused by a lack of response of platelet aggregation to ASA. In particular, because platelet aggregability was not investigated in these 2 patients, arterial emboli composed of atheromatous debris, fat, or coagulated erythrocytes, which are not expected to be influenced by antiplatelet agents, must be considered alternative causes.
Comparable experience regarding the effect of medical therapy on MES is limited. Follow-up examinations in a patient with symptomatic 70% carotid artery stenosis failed to show a relation between signal count and intensity of anticoagulation. 20 In a patient presenting with recurrent amaurosis fugax despite anticoagulation with warfarin (international normalized ratio, 2.4), MES were detected in repeated monitoring periods, probably caused by embolism from carotid artery plaque. 4 After ASA (300 mg/d) was started, amaurosis fugax events and MES stopped within 24 hours. In 2 patients with symptomatic intracranial stenoses receiving intravenous heparin (activated partial thromboplastin time Ͼ2-fold that of baseline level), high MES rates dropped to Ϸ20% of the baseline count 6 hours after an intravenous bolus of 800 mg ASA. 21 In contrast, embolic signals detected in symptomatic patients with atrial fibrillation were abolished by anticoagulation 22, 23 and reappeared after discontinuation of medication in a reported single case. 23 No drug effect on the frequency of MES was observed in patients with prosthetic cardiac valves, who were symptomatic despite sufficient anticoagulation by warfarin and additional heparin or intravenous ASA. 24 In patients with prosthetic valves, MES might be caused, at least to some extent, by gaseous emboli that cannot be discerned from solid particles and cannot be expected to respond to antithrombotic treatment. 25 In other conditions, the detection of MES as a parameter for cerebral emboli could be useful to monitor early effects of anticoagulants and antiplatelet agents. This might enable determination of appropriate individual medication, eg, by early diagnosis of an insufficient response of cerebral embolism to an antiplatelet agent, as presumed in 2 of our patients, as well as appropriate antithrombotic medication in patients with different sources of cerebral embolism.
MES and Cerebrovascular Events
In the 7 patients in whom MES frequency responded to ASA, no ischemic event was observed within a 90-day follow-up after the initiation of ASA prevention compared with 2.3 events in the month before. However, therapeutic regimens were inhomogeneous (additional endarterectomy was performed in 1 patient), and the number of investigated patients is far too small to draw conclusions about an association of MES and cerebral ischemia on the basis of our data. Nevertheless, further evaluation of a correspondence of TCD-detected microemboli with future ischemic events, as suggested recently, 26, 27 might enable new insights in pathophysiology and prevention of cerebral ischemia.
In summary, in patients with recent stroke from large-arterial-vessel disease, intravenous ASA can rapidly reduce cerebral microemboli of arterial origin, as detected by TCD. The onset of or change in an ASA medication should be considered when a potential correlation between the incidence and frequency of TCD-detected microemboli and the risk of future ischemic events is investigated.
